Kymera Therapeutics Inc To Discuss Data From KT-474 Phase 1 Trial Call Transcript
Good morning. I'd like to welcome everyone to Kymera Therapeutics conference call. (Operator Instructions) The call is being webcast live on the Investor and Media section of Kymera's website at kymeratx.com. This call is the property of Kymera Therapeutics and recording and reproduction or transmission of this call without express written consent of Kymera Therapeutics is strictly prohibited. Please note, the call is being recorded. I would now like to hand the call over to your host today, Bruce Jacobs, Chief Financial Officer. Please begin.
Good morning, everyone, and thank you for joining us today on our call to discuss the new KT-474 Phase I clinical trial data that we released this morning at the TPD Summit. These data are summarized in a press release that we issued this morning.
Additionally, the press release and the presentation slides used on this call can be found on the Investors section of our website at kymeratx.com.
Starting on Slide 2 of the accompanying presentation. During
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |